Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group MA.5 -- Cooperative Clinical Trial of Intensive CEF versus Standard CMF as Adjuvant Therapy for Breast Carcinoma in Premenopausal Patients With Histologically Involved Axillary Nodes

Hertel PB, Tu D, Ejlertsen B, Jensen M-B, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO. TIMP-1 in combination with HER2 and TOP2 for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients (ONLINE). Breast Cancer Res Treat 2011.


Canadian Cancer Trials Group PA.3 -- A Randomized Placebo Controlled Study of OSI-774 Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - Results from Canadian Cancer Trials Group PA.3: A phase III trial of gemcitabine plus erlotinib or placebo (ONLINE). Eur J Can 2011.


Rajput AB, Hu N, Varma S, Chen C-H, Ding K, Park PC, Chapman J-AW, SenGupta SK, Madarnas Y, Elliott BE, Feilotter HE. Immunohistochemical Assessment of Expression of Centromere Protein¿A (CENPA) in Human Invasive Breast Cancer. Cancers 3: 4212-27, 2011.


Eisenhauer EA. Optimal assessment of response in ovarian cancer. Ann Oncol 22: viii49-viii51, 2011.